Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from gene editing

Gene editing technology could be used to save species on the brink of extinction

Earth’s biodiversity is in crisis. An imminent “sixth mass extinction” threatens beloved and important wildlife. It also threatens to reduce the amount of genetic diversity – or variation – within species.

The Conversation

3 Bullish Biotech Stocks With Explosive Growth Trends

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

MarketBeat

Gene-edited pigs may soon enter the Canadian market, but questions about their impact remain

The Canadian government is currently considering approving the entry of gene-edited pigs into the food system.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

The Future of Cancer Treatment Is Here — And It Starts with the Right Clinical Trial

Cancer research no longer moves slowly; it advances rapidly. Revolutionary discoveries in precision medicine, immunotherapy, and gene editing emerge almost weekly, yet many patients still confront enormous hurdles when they look for cutting‑edge options.

International Business Times

Beyond de-extinction and dire wolves, gene editing can help today’s endangered species

Have you been hearing about the dire wolf lately? Maybe you saw a massive white wolf on the cover of Time magazine or a photo of “Game of Thrones” author George R.R. Martin holding a puppy named after a character from his books.

The Conversation

Designer DNA and Ethical Eating: The Brave New World of Biotech Arrives in the UK

Discover how gene editing and lab-grown meat are revolutionising healthcare and food in 2025, offering personalised treatments and sustainable, ethical meat alternatives.

International Business Times UK

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Baby born with rare life-threatening disorder makes medical history

Researchers hope what they learn from KJ will help other rare disease patients

The Independent UK

Biologist whose innovation saved the life of British teenager wins $3m Breakthrough prize

Prof David Liu is among the winners of 2025’s ‘Oscars of science’, with honours also going to researchers for landmark work on multiple sclerosis, particle physics and ‘skinny jabs’

The Guardian - UK

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

RNA editing is the next frontier in gene therapy – here’s what you need to know

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Scientists dismayed as UK ministers clear way for gene editing of crops - but not animals

Advocates urge government to allow ‘precision breeding’ to combat disease, but RSPCA warns of ethical dangers

Inverse

A Novel Discovery Hints At Why We Stop Producing New Brain Cells — And What We Can Do About It

A new study from Stanford Medicine shows how a gene editing tool identified a gene to knock out that could promote activation of neural stem cells.

Inverse

A Rose Without Thorns? How Gene Editing Is Giving Plants A Glow-Up

A geneticist recently discovered the gene that accounts for prickliness across a variety of plants, including roses.

The Conversation

Plants get a GMO glow-up: Genetically modified varieties are coming out of the lab and into homes and gardens

As any avid gardener will tell you, plants with sharp thorns and prickles can leave you looking like you’ve had a run-in with an angry cat. Wouldn’t it be nice to rid plants of their prickles entirely but keep the tasty fruits and beautiful flowers?

Get all your
news in one place.

100’s of premium titles.
One news app.

Inverse

Designer Babies Are Here — So Why Aren't We Talking About It?

The societal implications of this technology are still vast. And researchers can already start exploring the ethics by engaging communities well ahead of time.

Salon

Editing fetal genomes is on the horizon

Why ethical discussions with the target communities should happen sooner rather than later

The Conversation

Editing fetal genomes is on the horizon − a medical anthropologist explains why ethical discussions with the target communities should happen sooner rather than later

With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and funding pressures make real-time ethics oversight difficult.

StockNews.com

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Top News

Genetic Enhancement Key To Future Of Space Travel, Experts Say

Explore the potential of genetic enhancements in humans for space travel and the ethical considerations surrounding gene editing technology.

The Conversation

TB: gene editing could add new power to a 100-year-old vaccine

Tuberculosis dates back more than 9,000 years. It is the most infectious bacterial disease and in 2022 10.6 million people fell ill with it. Of these 23% occurred in Africa.

Axios

Gene editing's next big targets

Scientists are pursuing advances to address the technology's limitations and stretch gene editing to treat different types of diseases, improve agriculture, livestock and more.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Medical Pharmaceuticals

125 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.